ISRCTN27354239已完成未知
A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex versus an oral anti-diabetic in combination with sulfonylurea administered orally for the treatment of type two diabetes
Institut de Recherches Internationales Servier (France)0 个研究点目标入组 847 人开始时间: 2006年7月11日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 847
研究概览
简要总结
- 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/22723853
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female aged between 35 and 80 years
- •2. Body mass index (BMI) between 25 and 45 kg/m2
- •3. Treated in monotherapy with sulfonylurea
- •4. Presenting type 2 diabetes
排除标准
- •1. Type 1 diabetes
- •2. Known latent autoimmune diabetes in adults
研究者
相似试验
进行中（未招募）
不适用
A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to 150 mg tid) versus pioglitazone (30 mg od to 45 mg od) in combination with sulfonylurea administered orally for the treatment of type 2 diabetes.Type II DiabetesMedDRA version: 7.0Level: PTClassification code 10012613EUCTR2005-004798-60-CZI.R.I.S. Institut de Recherches Internationales Servier840
进行中（未招募）
不适用
A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to 150 mg tid) versus pioglitazone (30 mg od to 45 mg od) in combination with sulfonylurea administered orally for the treatment of type 2 diabetes.EUCTR2005-004798-60-DEI.R.I.S. Institut de Recherches Internationales Servier840
已完成
不适用
SWITCH - Sensing With Insulin pump Therapy to Control HbA1cNutritional, Metabolic, EndocrineType 1 diabetes mellitusISRCTN09806152Medtronic International Trading Sarl (Switzerland)160
进行中（未招募）
1 期
A 12-week, multicentre, multinational, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation), 2 puffs b.i.d., versus Seretide® 500/50 (fluticasone 500 µg plus salmeterol 50 µg/actuation), 1 inhalation b.i.d., in patients with Chronic Obstructive Pulmonary Disease.COPD (Chronic Obstructive Pulmonary Disease)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-014410-10-SKChiesi Farmaceutici SpA506
进行中（未招募）
不适用
A 12-week, multicentre, multinational, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation), 2 puffs b.i.d., versus Seretide® 500/50 (fluticasone 500 µg plus salmeterol 50 µg/actuation), 1 inhalation b.i.d., in patients with Chronic Obstructive Pulmonary Disease.EUCTR2009-014410-10-DEChiesi Farmaceutici SpA506